Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan's bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease
Stock Information for Akari Therapeutics Plc
Loading
Please wait while we load your information from QuoteMedia.